Understanding how interleukin-18 contributes to tau pathology in Alzheimer's disease
Deciphering the role of interleukin-18 as a driver of tau pathology in Alzheimer's disease
This study is looking at how a protein called IL-18 affects the buildup of harmful tau proteins in Alzheimer's disease, with the hope of finding new ways to slow down the disease for people living with it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11090553 on NIH RePORTER |
What this research studies
This research investigates the role of interleukin-18 (IL-18) in Alzheimer's disease, particularly how it affects tau pathology. The study aims to uncover the mechanisms by which IL-18 signaling is disrupted in Alzheimer's, leading to the accumulation of tau proteins that are harmful to brain function. Researchers will use both cell cultures and animal models to explore how changes in IL-18 signaling can influence tau pathology, potentially revealing new therapeutic targets. By understanding these processes, the research seeks to identify ways to mitigate the progression of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting inflammatory pathways in Alzheimer's disease, suggesting that this approach could be beneficial.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Laferla, Frank M — University of California-Irvine
- Study coordinator: Laferla, Frank M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.